ACAD
26.02
-0.25
-0.95%
AEMD
1.874
+0.064
+3.5193%
APRI
0.95
-0.01
-1.04%
ARNA
1.31
-0.05
-3.68%
ATEC
1.99
-0.04
-1.97%
CNAT
5.17
-0.09
-1.71%
CRXM
0.161
-0.009
-5.4118%
CYTX
1.03
0.00
0.00%
DXCM
68.65
-0.5
-0.72%
GNMK
13.14
+0.14
+1.08%
HALO
12.41
-0.19
-1.51%
ILMN
175.91
+2.15
+1.24%
INNV
0.133
+0.015
+12.807%
INO
7.88
-0.11
-1.38%
ISCO
1.32
-0.17
-11.41%
ISIS
57.56
0.00
0.00%
LGND
110.19
-3.31
-2.92%
LPTN
2.93
-0.08
-2.66%
MBVX
1.66
-0.13
-7.26%
MEIP
2.12
+0.15
+7.61%
MNOV
5.95
-0.1
-1.65%
MRTX
3.25
-0.05
-1.52%
MSTX
0.131
-0.007
-5.278%
NBIX
46.22
-2.42
-4.99%
NUVA
75.52
-0.26
-0.34%
ONCS
1.06
+0.08
+8.16%
ONVO
2.94
+0.09
+3.16%
OREX
2.97
+0.03
+1.02%
OTIC
12.35
-0.3
-2.37%
QDEL
24.91
-0.01
-0.04%
RCPT
231.96
0.00
0.00%
RGLS
1.375
+0.025
+1.852%
RMD
70.07
+0.02
+0.03%
SCIE
0.001
+0.00
+16.6667%
SPHS
2.46
-0.01
-0.40%
SRNE
1.75
+0.1
+6.06%
TROV
0.651
-0.039
-5.6377%
VICL
2.36
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
12.65
-0.25
-1.94%
ACAD
26.02
-0.25
-0.95%
AEMD
1.874
+0.064
+3.5193%
APRI
0.95
-0.01
-1.04%
ARNA
1.31
-0.05
-3.68%
ATEC
1.99
-0.04
-1.97%
CNAT
5.17
-0.09
-1.71%
CRXM
0.161
-0.009
-5.4118%
CYTX
1.03
0.00
0.00%
DXCM
68.65
-0.5
-0.72%
GNMK
13.14
+0.14
+1.08%
HALO
12.41
-0.19
-1.51%
ILMN
175.91
+2.15
+1.24%
INNV
0.133
+0.015
+12.807%
INO
7.88
-0.11
-1.38%
ISCO
1.32
-0.17
-11.41%
ISIS
57.56
0.00
0.00%
LGND
110.19
-3.31
-2.92%
LPTN
2.93
-0.08
-2.66%
MBVX
1.66
-0.13
-7.26%
MEIP
2.12
+0.15
+7.61%
MNOV
5.95
-0.1
-1.65%
MRTX
3.25
-0.05
-1.52%
MSTX
0.131
-0.007
-5.278%
NBIX
46.22
-2.42
-4.99%
NUVA
75.52
-0.26
-0.34%
ONCS
1.06
+0.08
+8.16%
ONVO
2.94
+0.09
+3.16%
OREX
2.97
+0.03
+1.02%
OTIC
12.35
-0.3
-2.37%
QDEL
24.91
-0.01
-0.04%
RCPT
231.96
0.00
0.00%
RGLS
1.375
+0.025
+1.852%
RMD
70.07
+0.02
+0.03%
SCIE
0.001
+0.00
+16.6667%
SPHS
2.46
-0.01
-0.40%
SRNE
1.75
+0.1
+6.06%
TROV
0.651
-0.039
-5.6377%
VICL
2.36
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
12.65
-0.25
-1.94%
Home » Archive by Category

Syndication

SCIENTIFIC INTERN (Paid Part Time) (La Jolla)

May 25, 2017 – 10:16 am

Scientific Internship
About Us
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiolo […

SCIENTIFIC INTERN (Paid Part Time) (La Jolla)

May 25, 2017 – 10:16 am

Scientific Internship
About Us
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiolo […

Executive Director, Biostatistics & Data Management – Retrophin – San Diego, CA

May 25, 2017 – 9:13 am

Create and maintain analyses, tables/listings/figures Perform programming validation and ensures all Quality Control efforts have been followed Provide guidance…From Retrophin – Thu, 25 May 2017 17:13:25 GMT – View all San Diego, CA jobs

Research Associate – Protein Expression & Purification (La Jolla, CA)

May 25, 2017 – 8:28 am

Inhibrx is clinical stage biologic immunotherapeutic company in La Jolla focused on the treatment of high unmet medical needs in oncology, infectious disease and inflammatory conditions. Inhibrx’s proprietary platforms enable fit-for-function biother […

Pharmaceutical, Biotechnology and Medical Device Job Opportunities (San Diego, Carlsbad)

May 25, 2017 – 8:03 am

Hiring companies include Thermo Fisher Scientific, Novartis, Covance, Organovo and more.
Search open positions in San Diego:
http://www.hirelifescience.com/seeker_jobs.aspx?q=1&keyword=any+job+title+or+keyword&country=US&city=San+Diego
Search open […]

Saturnino (Nino) Fanlo Joins Human Longevity, Inc. As Chief Financial Officer

May 25, 2017 – 8:00 am

Financial Industry Leader Brings 30 Years of Experience Leading Public, Private Companies; Raising Billions in Financing Rounds

SAN DIEGO, May 25, 2017 /PRNewswire/ — Human Longevity, Inc. (HLI), the genomics-based, health intelligence company, announced today that Saturnino (Nino) Fanlo will be joining the company as Chief Financial Officer, reporting to CEO Cynthia Collins. Fanlo brings decades of financial services acumen and strategic leadership to the role at HLI and will be instrumental in helping guide the company as it expands and strengthens commercialization and operations.

“Nino’s 30 years of financial services leadership especially his success in the fintech arena make him the ideal CFO for HLI,” said Collins. “Our company is poised for commercial success and I’m eager to have Nino as a key member of the team to ensure we remain laser focused on our goal of creating health intelligence in the healthcare market.”

“Joining Cindy, Craig Venter and the rest of the strong management team at HLI is a genuine honor. The technologies and products that HLI has created to positively impact the healthcare landscape are remarkable and the chance to contribute my skills and experience to this company is an exhilarating challenge,” said Fanlo.

Fanlo joins HLI from Social Finance, Inc. (Sofi), the largest and fastest growing online lender, where he served as President and Chief Financial Officer. Fanlo was a key leader at Sofi who worked hand in hand with the CEO and founder to design and build capital markets, loan sale, finance, and credit and loan operations there. He led five successful capital raises for more than $1.9 billion and moved the company from an $8 million to a $4.3 billion valuation in under five years. He was also a key architect of many of Sofi’s unique financial products.

Prior to Sofi Fanlo held a series of high level leadership roles in well-respected financial services firms. Before Sofi, he was a Senior Advisor at Golden Gate Capital where he helped to develop their $1 billion Credit Opportunity Fund and the $200 million Public Equity Fund. For 5 years, he served as the CEO of KKR Financial and CIO and Partner of KKR Asset Management where was responsible for capital raising, investment policy, portfolio selection and management, recruiting and development, and investor communications. He led the initial public offering of KKR Financial after just nine months of establishing this spinout. He also raised $4 billion in equity capital and $10 billion of permanent investment capital. 

Prior to that he also served as Executive Vice President and Treasurer of Wells Fargo & Co., where he was responsible for funding, capital and investment portfolio including cash management and liquidity operations. Other roles in his career include leadership positions with Goldman, Sachs & Co., Australian Capital Equity, and First Boston Corporation.

Fanlo received his Bachelor of Economics from Haverford College, Haverford, PA.

About Human Longevity, Inc™
Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

 

SOURCE Human Longevity, Inc.

WW Product Manager, Point-of-Care, BD Life Sciences – Becton Dickinson & Company – San Diego, CA

May 25, 2017 – 5:10 am

Minimum of 3 years of commercial experience, preferably in a biotechnology or life sciences industry. Job Description Summary BD Diagnostics Systems – Point-of…
From Becton Dickinson – Thu, 25 May 2017 13:10:39 GMT – View all San Diego, CA jobs

CRT II – CHARLES RIVER LABORATORIES – San Diego, CA

May 25, 2017 – 5:06 am

Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world….From Charles River Laboratories – Thu, 25 May 2017 13:06:40 GMT – View all San Diego, CA …

Amid Budget Concerns, NIH Preps Beta Test for Precision Medicine Plan

May 25, 2017 – 4:46 am

An ambitious plan to recruit 1 million U.S. volunteers and amass a treasure trove of their health information will start next week with a “beta test” that health officials hope to eventually expand…

[[Click headline to continue reading.]]

Phoenix Molecular Designs Announces New Preclinical Data for Targeted Triple Negative Breast Cancer (TNBC) Therapy

May 25, 2017 – 4:00 am

PMD-026 demonstrates 70% inhibition of ribosomal S6 kinase (RSK) signaling, blocking TNBC tumor growth in mice

VANCOUVER, British Columbia and SAN DIEGO, May 25, 2017 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today that it has made a significant research breakthrough in the development of a novel therapy for the treatment of triple negative breast cancer (TNBC) with new preclinical data for its lead asset, PMD-026, an oral small molecule that selectively targets RSK (p90 ribosomal S6 kinase) in TNBC and suppresses tumor growth.

In preclinical studies using the MDA-MB-231 TNBC model, PMD-026 was administered orally over a 28 day time course and demonstrated 70% inhibition of RSK signaling, blocking the growth of TNBC, and importantly, no adverse effects were observed. Within 30 min, PMD-026 was rapidly taken up by tumors whereby it shuts down the central signaling network needed for TNBC to grow. The preclinical model selected is resistant to a wide range of targeted therapies in which tumors do not respond to EGFR or mTOR inhibitors.  In addition, a head to head comparison of PMD-026 versus standard of care (doxorubicin) in the same mouse model showed equal inhibition of tumor growth – and most importantly – PMD-026 demonstrated a more favorable safety profile than doxorubicin.

“The need for new targeted therapies to help patients suffering with TNBC is urgent, but unfortunately novel treatments are extremely scarce.  We are addressing this unmet medical need through a novel, targeted approach by inhibiting critical kinases, such as RSK, known to be involved in the progression of numerous cancer indications,” said Sandra Dunn, Ph.D., Chief Executive Officer of PhoenixMD.  “Our recent favorable preclinical data on PMD-026, coupled with our robust intellectual property estate and leading research collaborations, give us greater confidence in our novel approach to treating cancer.  We look forward to building upon these preclinical results and initiating first-in-man studies with PMD-026 in 2018.”

“Disruptive therapies require thinking outside the box. PhoenixMD has taken a differentiated approach to developing inhibitors for TNBC by relying on functional screens to guide the selection of the fundamental kinase that drives the disease.  In the case of TNBC, RSK appears to be an essential kinase.  RSK inhibitors are new to the kinase scene and PMD-026 is headed for a first-in-class designation,” said Alan Lewis, Ph.D., Chair of the Scientific Advisory Board at PhoenixMD and CEO of Diavacs.  “The therapies being developed at PhoenixMD are designed to treat the most difficult cancer indications.  They are also promising for strategic combinations with check point inhibitors and/or standard of care therapies.  I look forward to working with the established team at PhoenixMD to advance PMD-026 into the clinic.”

Dr. Lewis has led biotech companies focused on developing kinase inhibitors including Signal, Celgene, and Ambit.  Further, he serves on the Board of numerous companies involved with the development of kinase inhibitors including BioMarin.

About Triple Negative Breast Cancer (TNBC) and RSK Kinases

Approximately 170,000 cases of TNBC are diagnosed every year worldwide and it is one of the most difficult breast cancer subtypes to treat due to lack of effective, targeted therapies.  TNBC also claims the lives of young women more than any other type of breast cancer due to a lack of understanding around the therapeutic bullseye.  It is also a very heterogeneous disease, therefore a common denominator across TNBC types was necessary to identify the bullseye.  Through genome-wide screens, RSK was identified as the prime target for TNBC by scientists at PhoenixMD. Currently, there are still no targeted therapies available for TNBC.

There are four types of RSK involved in cancer, known as RSK1-4, and each type has a unique role in the development of the disease. RSK1 is responsible for cancer cell invasion and is an important driver in the spread of cancer. RSK2 controls cancer cell growth, while RSK3 and RSK4 are associated with drug resistance.

RSK1 and RSK2 have been proven critical to the survival of patients with TNBC.  Over 90% of primary TNBC express high levels of RSK1 and RSK2.  Inhibiting RSK2 eliminates TNBC cells completely, including cancer stem cells, which give rise to cancer recurrence.  PhoenixMD, with its novel, targeted approach, is focused on creating patented cancer RSK inhibitors and companion diagnostics for cancer indications – initially in breast cancer – with the potential to treat blood, brain, ovarian, lung, skin, prostate, colon, head and neck cancers.

About PhoenixMD

PhoenixMD is a privately-held biopharmaceutical company designing precise cancer therapeutics and companion diagnostics by targeting kinases, a class of highly druggable enzymes to treat a wide range of oncology indications.  PhoenixMD is focused on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation.  Due to its emerging leadership in kinase inhibition, PhoenixMD has entered into partnerships with well-recognized academic and non-profit institutions such as the National Cancer Institute (NIH), University of Florida, Kyushu University, Mayo Clinic, and University of Hawaii Comprehensive Cancer Center. PhoenixMD is headquartered in Vancouver, British Columbia Canada with U.S. operations in San Diego, CA.  For more information, visit phoenixmd.ca.

Media Contact:
Amy Conrad
Juniper Point
Ph: (858) 366-3243
amy@juniper-point.com

SOURCE Phoenix Molecular Designs